NeOnc Technologies to Meet FDA on NEO212 Clinical Program
What happened
NeOnc Technologies Holdings, Inc. announced it is scheduled to meet with the FDA on November 17, 2026, at the FDA’s White Oak campus. The meeting is an End-of-Phase 1 Type B discussion regarding the NEO212 clinical development program. The company plans to seek feedback on the trial design, patient population, and evidence needed to support a future marketing application.
From manilatimes.net
Why it matters
The meeting follows the completion of the Phase 1 dose-escalation portion of the NEO212-01 clinical trial. During Phase 1, dose escalation was discontinued following a dose-limiting toxicity at 810 mg, and 610 mg was selected as the recommended Phase 2 dose. The outcome of this discussion could influence the future regulatory path of the therapy.
From manilatimes.net
Who's involved
Keep exploring
The entities involved
- FDA
-
White Oak
unincorporated area in Montgomery County, Maryland, United States, suburb of Washington, DC
Related events
- Matthew Zorn, Deputy General Counsel at the U.S. Dept., discussed issues around FDA review, concurrent with Marcus and Amber establishing VETS.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- FDA approval enables commercial opportunity involving CBRE Group.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.